EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
SECTION 11 OF 12 / Act

Market data and deal flow

Put market figures, pricing and deal activity in context.

11Pages
27Sources cited
17 Nov 2026Last updated
A calculator and procurement cost papers beside a medicine package
MARKET SIZE / SCOPE MATTERS

A common scale.
Different measures.

The approximately $128 billion calculation and the $41.6 billion obesity figure are overlapping measures, not additive market segments. IQVIA’s net-spending growth also uses a different economic basis from purchase expenditure.
USD BILLION075150

US GLP-1 spending across the broader category

Approximately $128 billion in 2025 — analyst calculationAnalyst calculation

ASHP, April 30, 2026

Scope and evidence basis

ASHP reported approximately 14% of $915 billion in total prescription spending. Multiplication gives $128.1 billion; rounded because the underlying share is approximate. ASHP says direct-to-consumer sales are excluded. Includes more than obesity treatment.

US GLP-1 antiobesity medicine spending

$41.6 billion, 2025Reported purchase expenditure

AJHP, April 30, 2026

Scope and evidence basis

Reported pharmaceutical purchase expenditure; not clinic revenue or manufacturer net revenue.

Increase in US net spending attributable to GIP/GLP-1 agonists

$14 billion, 2025 versus 2024Net-spending growth contribution

IQVIA, April 28, 2026

Scope and evidence basis

Growth contribution across diabetes and obesity—not total category spending.

Obesity-related component of that net-spending increase

$9.6 billion, 2025 versus 2024Net-spending growth contribution

IQVIA, April 28, 2026

Scope and evidence basis

Included within the $14 billion above; do not add the two figures.

Procurement controlled by the target provider cohort

Not establishedNot established

Research gap as of November 17, 2026

Scope and evidence basis

Requires provider counts, active patients, access-route mix and evidence of who controls expenditure.

Solid: published measureHatched: estimate / analyst calculation

Public evidence supports a large national medicine market, but this research did not identify a defensible market-size series specifically for providers with 10–100 prescribers.

Read the research

9 pages shown

Research quality self-assessment
9 / 10buyer fit
9 / 10depth
9 / 10search terms
8 / 10sources

The research’s own assessment; not an external rating.